Unified Patent Court
23 July 2024 Paris Central Division issues its first revocation judgment in dispute brought by Meril subsidiaries in Italy, Germany and India | Decision means infringement action by Edwards can resume at Munich Local Division | Damages worth €8m ($8.7m) | Gide, Marks & Clerk, Potter Clarkson among representatives.
20 February 2024
12 December 2023
Latest Features
Europe
Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity? Anna Leathley, Richard Newell & Sarah Mitchell of Carpmaels & Ransford explore.
Unified Patent Court
Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert.
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Big Pharma
Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.
Big Pharma
Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
Biotechnology
SPCs and trade secrets are just two issues set to be discussed at C5’s 11th Pharma & Biotech Patent Litigation, on February 26 and 27 in Amsterdam. LSIPR reports.
Big Pharma
From the Unified Patent Court to life sciences industrial strategy, there are many issues for Sean Dennehey to contend with as deputy CEO of the UK Intellectual Property Office. He talks to LSIPR about how he managed.
More News
28 November 2023 UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the court | Quality of rulings and tight timeframes blamed for lack of appeals.
23 November 2023 Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.
26 September 2023 An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.
21 September 2023 The spatial biology firm will appeal the Unified Patent Court’s preliminary injunction | NanoString accuses 10x of ‘misusing non-final court rulings…to eliminate competition in the spatial transcriptomics market’.
31 August 2023 Edwards Lifesciences files application for provisional measures at UPC | Hearing details adds to existing listed by the court for 10x Genomics versus NanoString.
22 August 2023 UPC announces public hearings at Munich court | Proceedings relate to the dispute over patents covering the in-situ detection of analytes.
27 June 2023 UPC Administrative Committee 'voted unanimously' to approve Milan says Italian politician | Court will hear patent cases related to “pharmaceutical, phytosanitary, agri-food and fashion” | Chemistry and metallurgy moving to Munich, excluding SEPs.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox